FDA
-
-
-
-
-
-
-
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
-
-
-
-
-
-
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
-
-
-
-
-
-
-
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
-
-
-
-
-
-
-
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
-
-
-
-
-
-
-
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
-
-
-
-
-
-
-
7 top biotech picks for 2025 according to Wells Fargo
-
-
-
-
-
-
-
Beam Therapeutics (BEAM) Reports Progress Across Base Editing Portfolio, Outlines 2023 Milestones
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

